Avidity Biosciences Total Liabilities

Avidity Biosciences (RNA) currently reports a total liabilities of $58M as of March 2026. That compares with $130M in the prior-year period — down 55.3% year over year. Use the charts on this page to explore Avidity Biosciences's total liabilities history and peer comparisons.

Avidity Biosciences's total liabilities decreased from $130M to $58M — a 55.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avidity Biosciences reported $58M in total liabilities as of March 2026. That compares with $130M in the prior-year period — down 55.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $58M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Avidity Biosciences, and consider following RNA for alerts when major investors trade the stock.

Avidity Biosciences is classified in the Healthcare sector. On total liabilities, it currently shows $58M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RNA with unrelated industries.